534 related articles for article (PubMed ID: 18657182)
1. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
Loría F; Petrosino S; Mestre L; Spagnolo A; Correa F; Hernangómez M; Guaza C; Di Marzo V; Docagne F
Eur J Neurosci; 2008 Aug; 28(4):633-41. PubMed ID: 18657182
[TBL] [Abstract][Full Text] [Related]
2. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis.
Loría F; Petrosino S; Hernangómez M; Mestre L; Spagnolo A; Correa F; Di Marzo V; Docagne F; Guaza C
Neurobiol Dis; 2010 Jan; 37(1):166-76. PubMed ID: 19815071
[TBL] [Abstract][Full Text] [Related]
3. The neurobiology and evolution of cannabinoid signalling.
Elphick MR; Egertová M
Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
5. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis.
Ortega-Gutiérrez S; Molina-Holgado E; Arévalo-Martín A; Correa F; Viso A; López-Rodríguez ML; Di Marzo V; Guaza C
FASEB J; 2005 Aug; 19(10):1338-40. PubMed ID: 15941768
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
Jhaveri MD; Richardson D; Robinson I; Garle MJ; Patel A; Sun Y; Sagar DR; Bennett AJ; Alexander SP; Kendall DA; Barrett DA; Chapman V
Neuropharmacology; 2008 Jul; 55(1):85-93. PubMed ID: 18534634
[TBL] [Abstract][Full Text] [Related]
7. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
8. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.
Docagne F; Muñetón V; Clemente D; Ali C; Loría F; Correa F; Hernangómez M; Mestre L; Vivien D; Guaza C
Mol Cell Neurosci; 2007 Apr; 34(4):551-61. PubMed ID: 17229577
[TBL] [Abstract][Full Text] [Related]
9. From endocannabinoid profiling to 'endocannabinoid therapeutics'.
Ligresti A; Petrosino S; Di Marzo V
Curr Opin Chem Biol; 2009 Jun; 13(3):321-31. PubMed ID: 19497779
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2.
McHugh D; Tanner C; Mechoulam R; Pertwee RG; Ross RA
Mol Pharmacol; 2008 Feb; 73(2):441-50. PubMed ID: 17965195
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
Manterola A; Bernal-Chico A; Cipriani R; Canedo-Antelo M; Moreno-García Á; Martín-Fontecha M; Pérez-Cerdá F; Sánchez-Gómez MV; Ortega-Gutiérrez S; Brown JM; Hsu KL; Cravatt B; Matute C; Mato S
Biochem Pharmacol; 2018 Nov; 157():189-201. PubMed ID: 30075103
[TBL] [Abstract][Full Text] [Related]
12. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
13. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Petrosino S; Di Marzo V
Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid signalling in the enteric nervous system.
Galligan JJ
Neurogastroenterol Motil; 2009 Sep; 21(9):899-902. PubMed ID: 19689654
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid receptors and their ligands.
Pertwee RG; Ross RA
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):101-21. PubMed ID: 12052030
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid system and gut-brain signalling.
Storr MA; Sharkey KA
Curr Opin Pharmacol; 2007 Dec; 7(6):575-82. PubMed ID: 17904903
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids for the treatment of inflammation.
Ashton JC
Curr Opin Investig Drugs; 2007 May; 8(5):373-84. PubMed ID: 17520866
[TBL] [Abstract][Full Text] [Related]
18. Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases.
Moreno-Martet M; Mestre L; Loría F; Guaza C; Fernández-Ruiz J; de Lago E
Neurosci Lett; 2012 Feb; 508(2):67-72. PubMed ID: 22206832
[TBL] [Abstract][Full Text] [Related]
19. Gut feelings about the endocannabinoid system.
Di Marzo V; Piscitelli F
Neurogastroenterol Motil; 2011 May; 23(5):391-8. PubMed ID: 21481098
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid system and neuroinflammation: implications for multiple sclerosis.
Correa F; Docagne F; Mestre L; Loría F; Hernangómez M; Borrell J; Guaza C
Neuroimmunomodulation; 2007; 14(3-4):182-7. PubMed ID: 18073512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
